A new partnership has formed between BERG and Sanofi Pasteur that will look to assess potential biomarkers of influenza vaccination outcomes through the use of artificial intelligence (AI). BERG is a modern biopharmaceutical company that combines technology with biology. Sanofi Pasteur is a global leader in the vaccine market.
The influenza virus affects between 10 and 20 percent of the U.S. population every year. Apply this nationwide, and that equates to almost 200,000 hospital stays and tens of thousands of deaths per year due to related complications. The way to prevent becoming one of those statistics is to get an annual flu vaccination, according to the U.S. Centers for Disease Control and Prevention (CDC). It’s recommended for most people aged six months and older, although there are some rare exceptions.
“We are thrilled to work with Sanofi Pasteur, a world leader in the vaccine industry. The Berg Interrogative Biology includes multi-omic profiling of samples from individuals participating in a longitudinal study with Sanofi Pasteur licensed vaccines and subsequent use of our bAIcis artificial intelligence tool with the aim to identify molecular signatures and potential biomarkers indicative of breadth and durability of the Influenza vaccine immunological response,” said co-founder, president, and chief executive officer of BERG, Niven R. Narain.
The bAIcis artificial intelligence is used by BERG’s Interrogative Biology platform to analyze large amounts of molecular and clinical data. It’s proven to be successful in extracting relevant and useful information from large datasets and is already being used by a number of different companies to enable prescriptive and predictive alalytics. BERG is proud to be an innovator in precision medicine, and as a result of this has using AI in hopes of discovering more predictive and prognostic biomarkers in diabetes, eurology, and oncology.
“The Sanofi Pasteur project showcases the versatility and ability of our technology to address important health outcomes questions in the area of infectious diseases both at the individual and population levels,” said Slava Akmaev, senior vice president and chief analytics officer at BERG. “We are excited to work with Sanofi Pasteur to discover biomarkers of the flu vaccine response, and ultimately on helping to prevent the spread of this debilitating, and sometimes fatal illness.”
Source Berg
